Dalantercept
Also known as: ACE-041, ALK1-Fc, Dalantercept
Source Dalantercept at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dalantercept is a recombinant activin receptor type IIA-Fc fusion protein investigated for the treatment of solid tumors by inhibiting ligand-driven angiogenesis.
Mechanism of Action
Soluble activin receptor type IIA-Fc decoy that binds activin A, BMP9 and related ligands, blocking ALK1 signaling and tumor angiogenesis.
Routes of Administration
Goals & Uses
- solid tumor therapyOncologyModerate
- Hepatocellular carcinoma treatmentOncologyLow
- Renal cell carcinoma treatmentOncologyModerate
- Anti-tumor angiogenesisOncologyModerate
- Head and neck squamous cell carcinoma treatmentOncologyLow
Contraindications
- hypersensitivity to the drug or its excipientsAllergyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hereditary hemorrhagic telangiectasia (HHT)Genetic Vascular DisorderHigh
Adverse Effects
- TelangiectasiasDermatologic/vascularCommon
- Peripheral edemaFluid BalanceCommonSwelling of the arms or legs
- HypertensionCardiovascularCommonHigh blood pressure
- EpistaxisVascular/bleedingCommon
- FatigueGeneralCommonLow energy or tiredness
- Pulmonary hypertensionCardiovascular/pulmonaryRare
Drug Interactions
- AxitinibModerate
- none identifiedLow
- Antihypertensive agentsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with pre-existing vascular malformationsVascularRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trials ongoing; not authorized.
- United StatesInvestigationalUnder IND; no FDA approval.
No regulatory approval in any jurisdiction as of 2026; studied in phase I/II clinical trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dalantercept?
Dalantercept is a recombinant activin receptor type IIA-Fc fusion protein investigated for the treatment of solid tumors by inhibiting ligand-driven angiogenesis.
What is Dalantercept used for?
Dalantercept is educationally associated with: solid tumor therapy, Hepatocellular carcinoma treatment, Renal cell carcinoma treatment, Anti-tumor angiogenesis, Head and neck squamous cell carcinoma treatment. Educational only — not medical advice.
How is Dalantercept administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Dalantercept?
Reported adverse effects include: Telangiectasias, Peripheral edema, Hypertension, Epistaxis, Fatigue, Pulmonary hypertension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dalantercept?
Recorded contraindications: hypersensitivity to the drug or its excipients, Severe hepatic impairment, Pregnancy, Hereditary hemorrhagic telangiectasia (HHT). Consult a qualified clinician before use.